[RILPIVIRINE -- a novel HIV-1 non-nucleoside reverse transcriptase inhibitor]. 2013

Svatava Snopková, and Kateřina Havlíčková, and Pavel Polák, and Pavel Šlesinger, and Petr Husa
Department of Infectious Diseases, Medical faculty of Masaryk University, The University Hospital Brno, Czech Republic. svatava.snopkova@fnbrno.cz

The article summarizes the basic facts about the pharmacokinetic profile, metabolism and drug interactions of rilpivirine (RPV). This is the latest orally administered second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for antiretroviral-naive patients with HIV-1 infection. Conformational flexibility and adaptability are the factors that dominantly determine the high resistance barrier of RPV and are the unique features of diarylpyrimidine inhibitors (DAPY inhibitors - 2nd generation NNRTIs). Multicentre studies ECHO and THRIVE are also reviewed. Current guidelines for the treatment of HIV/AIDS are mentioned as well as the role of RPV in current therapeutic regimens.

UI MeSH Term Description Entries
D009570 Nitriles Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE. Nitrile
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068696 Rilpivirine A diarylpyrimidine derivative and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 that is used in the treatment of HIV INFECTIONS. It is also used in combination with other ANTI-HIV AGENTS, since ANTIVIRAL DRUG RESISTANCE emerges rapidly when it is used alone. R278474,Rilpivirine HCl,Rilpivirine Hydrochloride,TMC 278,TMC-278,TMC278,278, TMC,HCl, Rilpivirine,Hydrochloride, Rilpivirine
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse

Related Publications

Svatava Snopková, and Kateřina Havlíčková, and Pavel Polák, and Pavel Šlesinger, and Petr Husa
July 2009, Expert opinion on investigational drugs,
Svatava Snopková, and Kateřina Havlíčková, and Pavel Polák, and Pavel Šlesinger, and Petr Husa
February 2013, The Journal of antimicrobial chemotherapy,
Svatava Snopková, and Kateřina Havlíčková, and Pavel Polák, and Pavel Šlesinger, and Petr Husa
January 1992, Advances in experimental medicine and biology,
Svatava Snopková, and Kateřina Havlíčková, and Pavel Polák, and Pavel Šlesinger, and Petr Husa
January 2012, Antiviral therapy,
Svatava Snopková, and Kateřina Havlíčková, and Pavel Polák, and Pavel Šlesinger, and Petr Husa
August 2008, Current opinion in investigational drugs (London, England : 2000),
Svatava Snopková, and Kateřina Havlíčková, and Pavel Polák, and Pavel Šlesinger, and Petr Husa
January 2014, Expert review of anti-infective therapy,
Svatava Snopková, and Kateřina Havlíčková, and Pavel Polák, and Pavel Šlesinger, and Petr Husa
January 2013, AIDS (London, England),
Svatava Snopková, and Kateřina Havlíčková, and Pavel Polák, and Pavel Šlesinger, and Petr Husa
May 2013, Annals of medicine,
Svatava Snopková, and Kateřina Havlíčková, and Pavel Polák, and Pavel Šlesinger, and Petr Husa
January 1996, Advances in experimental medicine and biology,
Svatava Snopková, and Kateřina Havlíčková, and Pavel Polák, and Pavel Šlesinger, and Petr Husa
December 2017, Biochemistry. Biokhimiia,
Copied contents to your clipboard!